Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Raw Materials (2022 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Raw Materials for 4 consecutive years, with $7.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Raw Materials rose 43.01% to $7.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $7.2 million, a 43.01% increase, with the full-year FY2024 number at $6.8 million, up 46.51% from a year prior.
  • Raw Materials was $7.2 million for Q3 2025 at Rhythm Pharmaceuticals, up from $4.5 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $7.2 million in Q3 2025 to a low of $2.3 million in Q2 2023.
  • A 4-year average of $4.4 million and a median of $4.6 million in 2023 define the central range for Raw Materials.
  • Biggest YoY gain for Raw Materials was 82.2% in 2024; the steepest drop was 31.3% in 2024.
  • Rhythm Pharmaceuticals' Raw Materials stood at $2.7 million in 2022, then soared by 69.91% to $4.6 million in 2023, then surged by 46.51% to $6.8 million in 2024, then rose by 5.95% to $7.2 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Raw Materials are $7.2 million (Q3 2025), $4.5 million (Q2 2025), and $5.0 million (Q1 2025).